Company DNA Chip Research Inc.

Equities

2397

JP3548590003

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
1,046 ^JPY	-0.66%		-6.36%	+51.16%

Mar. 28	DNA Chip Research Inc. announced that it has received ¥269.99972 million in funding from Mitsui Chemicals, Inc.	CI
Feb. 08	DNA Chip Research Inc. announced that it expects to receive ¥269.99972 million in funding from Mitsui Chemicals, Inc.	CI

DNA Chip Research Inc. is primarily engaged in DNA chip-related analysis and next-generation sequence related technology research business, and diagnostic business which is engaged in the sales of medical-related equipment centered on EGFR-NGS Check. The Contract Research segment is engaged in the microarray, next-generation sequencing experiment analysis to universities and research institutes, pharmaceutical and food companies. The Diagnostic segemnt utilizes genetic analysis technology to disseminate tests corresponding to social needs on personalized medicine and undiseased society. The main menu of the diagnostic business is EGFR-NGS Check. The Research and Development segment includes research on cancer diagnosis technology using next generation sequencer, as well as the development of RNA check.

Number of employees: 36

JPY in Million	2022	Weight	2023	Weight	Delta
Research 90.7 %	376	87.9 %	297	90.7 %	-21.07%
Diagnostic 9.3 %	52	12.1 %	31	9.3 %	-40.90%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 100.0 %	428	100.0 %	328	100.0 %	-23.46%

Managers	Title	Age	Since
Ryo Matoba PSD	President	59	06-03-31
Keiji Sato BRD	Director/Board Member	45	15-04-30
Kunio Yamada BRD	Director/Board Member	70	15-05-31
Tsukasako Nakano IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Ryo Matoba PSD	President	59	06-03-31
Tokio Katayama BRD	Director/Board Member	78	14-05-31
Kunio Yamada BRD	Director/Board Member	70	15-05-31
Keiji Sato BRD	Director/Board Member	45	15-04-30
Takaaki Sato BRD	Director/Board Member	64	19-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	6,767,174	4,581,162 ( 67.70 %)	3,138 ( 0.0464 %)	67.70 %

Name	Equities	%	Valuation
MITSUI CHEMICALS, INC. 14.76 %	937,474	14.76 %	10 M ¥
Mamoru Fujii 4.958 %	315,000	4.958 %	3 M ¥
Nippon Molymer Co., Ltd. 3.054 %	194,000	3.054 %	2 M ¥
Hiroshi Murakami 2.775 %	176,300	2.775 %	2 M ¥
Ichita Kobashi 2.553 %	162,200	2.553 %	2 M ¥
Hichiro Edamatsu 1.473 %	93,600	1.473 %	989 527 ¥
Kouyou Takekawa 1.398 %	88,800	1.398 %	938 782 ¥
Atsuhiko Mori 1.333 %	84,700	1.333 %	895 437 ¥
Garyo Ueno 1.165 %	74,000	1.165 %	782 318 ¥
Dna Chip Research Restricted Stock Compensation Plan 0.6296 %	40,000	0.6296 %	422 875 ¥

Name	Equities	%	Valuation
DNA CHIP RESEARCH INC. 0.05%	3,100	0.05%	32,773 $

DNA Chip Research, Inc.

Suzue Baydium, 5/F 1-15-1 Kaigan

105-0022, Tokyo

http://www.dna-chip.co.jp

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
DNA CHIP RESEARCH INC.	+51.16%	45.95M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.23%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research